Filter By Category
Archives
Share on -
Gimeracil
Generic Name: Gimeracil
small molecule; dihydropyrimidine dehydrogenase inhibitor used in fluoropyrimidine combinations; component of S-1/Teysuno in some regions.
ABSTRACT
Gimeracil is a small-molecule API. It is described as dihydropyrimidine dehydrogenase inhibitor used in fluoropyrimidine combinations; clinical use and safety vary by indication, regulatory status and product label.
DOSAGE
Not used as standalone therapy; dosage is according to tegafur/gimeracil/oteracil combination product label.
SIDE EFFECTS
- Fluoropyrimidine-associated nausea, diarrhea or stomatitis in combinations
- Myelosuppression in combination regimens
- Fatigue or appetite decrease
- Liver enzyme changes
- Hand-foot syndrome or rash depending on regimen
ALLERGIC REACTIONS
(These symptoms may indicate an allergic reaction and require medical attention.)
- Urticaria or generalized rash
- Facial, lip, tongue or throat swelling
- Bronchospasm, dyspnea or wheeze
- Anaphylaxis (rare but serious)
DRUG INTERACTIONS
- Concomitant fluoropyrimidines, brivudine/sorivudine analogs or DPD inhibitors can cause severe toxicity
- Warfarin/anticoagulants may require closer monitoring with fluoropyrimidine regimens
- Renal impairment may increase exposure in S-1 combinations
PRECAUTIONS
- Assess renal function and fluoropyrimidine toxicity risks
- Do not substitute standalone gimeracil for combination product guidance
- Monitor CBC, GI toxicity and mucositis
- Pregnancy/lactation risk assessment is required
WARNINGS
- Severe fluoropyrimidine toxicity can be life-threatening
- Contraindicated combinations must be checked before treatment
- Not a standalone approved anticancer therapy
Share on -
. Developed by